论文部分内容阅读
70％～80％的晚期生殖细胞瘤(germcell tumor,GCT)患者经以顺铂为主的诱导化疗可获长期CR。对上述方案无效最终将死于该病的另外20％～30％病人,显然必须给予更有效的治疗。 1988年12月至1990年12月,作者以大剂量化疗和自体骨髓移植(AUBMR)治疗29例耐药GCT患者。病人分为两组,A组16例,均为就诊时血清肿瘤标志物下降时间延长的高危病人(两周期CTX,VLB,ACTD,BLM和DDP诱导治疗后AFP半衰期超过7天,HCG半衰期超过3天);B组13例,均为标准诱导方案和以顺铂为主解救化疗后复发或对顺铂加异环磷酰胺为主化疗不完全有效(incomplete response,IR)病人。所有病人K-
70% to 80% of patients with advanced germ cell tumors (GCT) are treated with cisplatin-based chemotherapy for long-term CR. The ineffectiveness of the above-mentioned regimen will eventually result in death in another 20% to 30% of the patients, which obviously have to be given more effective treatment. From December 1988 to December 1990, the authors treated 29 patients with resistant GCT with high-dose chemotherapy and autologous bone marrow transplantation (AUBMR). The patients were divided into two groups. A group of 16 patients were all high-risk patients with prolonged decline of serum tumor markers at the time of treatment (AFP half-life more than 7 days after two cycles CTX, VLB, ACTD, BLM and DDP induction therapy, HCG half- Day); B group of 13 cases, both standard induction regimens and cisplatin-based chemotherapy to relapse after chemotherapy or cisplatin plus ifosfamide-based chemotherapy is not fully effective (incomplete response, IR) patients. All patients K-